Financial Performance - The company's consolidated net profit attributable to shareholders for the year ended December 31, 2024, was CNY 230,756,619.25, representing a decrease of 27.98% compared to the previous year[6]. - The total operating revenue for 2024 was CNY 3,629,804,492.14, reflecting a decline of 4.44% from the previous year[24]. - The net cash flow from operating activities decreased by 10.01% to CNY 398,766,454.60 compared to the previous year[24]. - The total assets as of the end of 2024 were CNY 4,556,298,077.73, a decrease of 2.58% from the end of 2023[24]. - The net assets attributable to shareholders increased by 3.04% to CNY 2,462,279,280.80 compared to the end of 2023[24]. - Basic earnings per share decreased by 26.43% to CNY 0.5579 compared to CNY 0.7583 in the previous year[25]. - Net profit attributable to shareholders decreased by 27.98% year-on-year, with adjustments reflecting an increase of CNY 2.7333 million in the current period[25]. - The weighted average return on equity fell to 9.54%, down from 13.91% in the previous year, a decrease of 4.37 percentage points[25]. - The total profit achieved was CNY 33,530.76 million, down 27.17% year-on-year[52]. - The net profit attributable to shareholders was CNY 23,075.66 million, reflecting a decline of 27.98% compared to the previous year[52]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 3.6 per 10 shares (including tax) based on the number of shares on the dividend record date[6]. - The company reported a cumulative undistributed profit of CNY 1,229,469,847.51 as of December 31, 2024[6]. - The cumulative cash dividend over the last three accounting years reached 556,610,752.10 RMB, with a cash dividend ratio of 180.53% based on the average annual net profit of 308,326,012.52 RMB[163]. Research and Development - R&D investment reached 235 million yuan, a year-on-year increase of 61.70%, with 56 new R&D projects initiated and a total of 119 projects under development[38]. - Research and development expenses increased by 47.72% to CNY 220,204.53 million, indicating a strategic focus on innovation[54]. - The total R&D investment for 2024 is CNY 234.54 million, accounting for 6.46% of total revenue and 12.15% of industrial revenue[69]. - The company is focusing on the development of innovative drugs in the fields of oncology and sleep medicine, aiming to create new growth points[120]. - The company has received approval for two projects: Compound Acetaminophen and Dapoxetine Hydrochloride tablets, while several other projects are in various stages of clinical research and registration[90][91]. Market and Product Development - The company launched 5 new products during the year, including Yimucao Granules and Qingbai Wash Liquid[34]. - The market share of the company's gynecological product, Qianjin Capsule, reached 25.8%, while the sales scale of Bu Xue Yi Mu Granules exceeded 180 million yuan, with a market share of 10.81%[36]. - The company is focusing on expanding its product line in women's health, with unique products like Gynecology Qianjin tablets and Blood Supplement Yimother pills[87]. - The company is actively pursuing international registration for its products, indicating a strategy for market expansion[88]. Operational Efficiency - The average inventory amount decreased by 25% year-on-year, and the average inventory turnover days reduced by 4 days[40]. - The production efficiency improvements resulted in a 12% increase in the output of dosage forms, reaching 3 billion tablets[40]. - The company has established a new organizational structure with 6 primary flexible teams and recruited 92 high-potential talents during the reporting period[36]. - The company has implemented a digital transformation strategy to reduce costs and improve efficiency across its operations[118]. Environmental and Social Responsibility - The company has invested 605.8 million RMB in environmental protection during the reporting period[169]. - The company has implemented a waste gas collection and treatment system at the raw material drug workshop, with online detection systems installed[178]. - Total investment in social responsibility projects amounted to CNY 2.7859 million, benefiting over 24.57 million people through the "Hello Qianjin" public welfare project[179]. - The "Hello Qianjin - Women's Health China Tour" project has reached over 60 million women since its launch in 2016, with activities conducted in over 1,600 schools and 200 companies[180]. Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for senior management, linking their compensation to the company's operational performance[127]. - The company has a total of 5,270 employees, with 1,833 in the parent company and 3,437 in major subsidiaries[152]. - The company has undergone a board restructuring with several new appointments, including the election of Chen Jun and Di Wen as directors[140]. - The company has a new compensation plan for senior management for the years 2024 to 2026[138]. Future Outlook - The company aims to achieve a turnaround by Q2 2025, with specific performance targets set[132]. - The company plans to increase R&D investment to at least 10% of industrial sales, enhancing collaboration with external partners and expanding its R&D team[118]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million yuan earmarked for potential deals[133]. - The company has provided a positive outlook for the next quarter, projecting a revenue growth of 10% to 1.32 billion yuan[134].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,005,023,395.38, representing a year-on-year increase of 0.43% compared to CNY 1,000,740,881.98 in the same period last year[4] - Net profit attributable to shareholders increased by 15.06% to CNY 53,155,316.53 from CNY 46,198,047.86 year-on-year[4] - The basic earnings per share rose by 16.43% to CNY 0.1254, up from CNY 0.1077 in the previous year[5] - Net profit for Q1 2025 was ¥72,319,004.16, up from ¥61,007,849.98 in Q1 2024, reflecting a growth of 18.6%[20] - The net profit attributable to shareholders of the parent company for Q1 2025 was ¥53,155,316.53, compared to ¥46,198,047.86 in Q1 2024, an increase of 15.5%[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.1254, up from ¥0.1077 in Q1 2024, marking a rise of 16.0%[20] - The company reported a total comprehensive income of ¥72,319,004.16 for Q1 2025, compared to ¥61,007,602.99 in Q1 2024, an increase of 18.6%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,661,288,930.48, reflecting a 2.30% increase from CNY 4,556,298,077.73 at the end of the previous year[5] - The company's total current assets decreased from 2,728,924,172.75 RMB as of December 31, 2024, to 2,539,178,640.44 RMB as of March 31, 2025, a decline of approximately 6.9%[14] - Total current liabilities increased from 1,332,793,102.67 RMB to 1,365,133,748.56 RMB, an increase of approximately 2.4%[15] - Total liabilities as of the reporting date were ¥1,447,823,368.47, compared to ¥1,417,151,519.88 in the previous period, an increase of 2.2%[18] - Total equity attributable to shareholders of the parent company was ¥2,517,440,737.20, up from ¥2,462,279,280.07, reflecting a growth of 2.24%[18] Cash Flow - The net cash flow from operating activities improved by 26.93%, with a net outflow of CNY 124,368,913.13 compared to CNY 170,209,301.10 in the same period last year[4] - Operating cash inflow totaled $892.80 million, an increase from $883.31 million year-over-year[22] - Operating cash outflow amounted to $1,017.17 million, down from $1,053.51 million year-over-year[22] - Net cash flow from operating activities was -$124.37 million, an improvement from -$170.21 million year-over-year[22] - The ending cash and cash equivalents balance was $921.32 million, down from $1,730.24 million year-over-year[23] - The company reported a decrease in cash and cash equivalents due to negative cash flow from operating and investing activities[23] Receivables and Expenses - Accounts receivable increased by 51.46%, primarily due to changes in the company's credit policy[8] - Other receivables surged by 494.03%, mainly due to an increase in advance payments and guarantees[8] - Financial expenses rose by 126.22%, attributed to a decrease in bank deposit income[8] - Research and development expenses for Q1 2025 totaled ¥61,461,708.51, slightly higher than ¥60,460,413.73 in Q1 2024, an increase of 1.66%[19] - The company reported a significant increase in other receivables from 15,745,373.69 RMB to 93,532,170.01 RMB, an increase of about 493.5%[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,636[10] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., holds 119,381,136 shares, accounting for 28.1% of total shares[10] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[23] - The management team remains focused on improving operational efficiency and cash flow management strategies moving forward[22]

株洲千金药业股份有限公司董事会 关于独立董事独立性自查情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等法律法规、规范性文件的要 求，株洲千金药业股份有限公司（以下简称"公司"）董事会就公司 在任独立董事周季平先生、狄文先生、马理先生的独立性情况进行评 估并出具如下专项意见： 经核查上述人员的任职经历以及其签署的相关自查文件，公司上 述在任独立董事未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害 关系或其他可能妨碍其进行独立客观判断的关系，符合《上市公司独 立董事管理办法》《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》等相关规则中对独立董事应具有独立性的相关要求。 株洲千金药业股份有限公司 董事会 2025 年 4 月 25 日 ...

公司代码：600479 公司简称：千金药业 株洲千金药业股份有限公司 2024年度内部控制评价报告 株洲千金药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表………………第 3 页 三、附件………………………………………………………………第 4—7 页 （一）本所营业执照复印件 ………………………………………第 4 页 （二）本所执业证书复印件 ………………………………………第 5 页 （三）本所签字注册会计师执业证书复印件 …………………第 6-7 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 为了更好地理解千金药业公司 2024 年度非经营性资金占用及其他关联资金 往来情况，汇总表应当与已审的财务报表一并阅读。 二、管理层的责任 千金药业公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会 公告〔2022〕26 号）和《上海证券交易所上市公司自律监管指南第 2 号——业 务办理（2024 年 5 月修订）》（上证函〔2024〕1476 号）的规定编制汇总表， 并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 第 1 页 共 7 页 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-029 株洲千金药业股份有限公司 | | | | | 营业 | 营业 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 收入 | 成本 | 毛利率 | | | | | 毛利 | 比上 | 比上 | 比上年 | | 分行业 | 营业收入 | 营业成本 | 率（%） | 年同 | 年同 | 同期增 | | | | | | 期增 | 期增 | 减（%） | | | | | | 减（%） | 减（%） | | | 药品生 | | | | | | 减少 | | | 530,222,497.67 | 175,258,545.39 | 66.95 | 7.21 | 11.75 | 1.34 个 | | 产 | | | | | | 百分点 | | 中药材 | | | | | | 减少 | | 及饮片 | 15,719,733.38 | 14,157,680.18 | 9.94 | -24.25 | -19.24 | 5.59 个 | | 生产 | | | | | | 百分点 | | 药品批 | | ...

株洲千金药业股份有限公司 董事会审计委员会 2024 年度履职情况报告 根据《上市公司治理准则》《上海证券交易所上市公司自律监管 指引第1号——规范运作》《公司章程》和《董事会审计委员会实施 细则》等有关规定，2024年度，株洲千金药业股份有限公司（以下简 称"公司"）董事会审计委员会本着勤勉尽责的原则，积极开展各项 工作，切实有效地发挥审查、监督作用。现就2024年度的履职情况汇 报如下: 一、审计委员会基本情况 公司于 2024 年 1 月 15 日召开第十一届董事会第一次会议，审议 通过《关于选举公司第十一届董事会战略、审计、提名、薪酬与考核 四个专门委员会成员的议案》。公司新一届董事会审计委员会由三名 董事组成，分别是独立董事周季平、独立董事马理、独立董事狄文， 主任委员由会计专业独立董事周季平担任。 二、审计委员会年度会议召开情况 报告期内，第十一届董事会审计委员会根据《上市公司治理准则》 《公司章程》《董事会审计委员会实施细则》及其他有关规定，积极 履行职责。2024年度，审计委员会共召开了7次会议，全体委员亲自 出席了全部会议。主要就公司提交的改聘会计师事务所、定期报告（含 财务报告）、内部控制 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-024 株洲千金药业股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | --- | --- | --- | --- | --- | | 成立日期 | 2011 年 7 月 18 日 | 组织形式 特殊普通合伙 | | | | 注册地址 | | 浙江省杭州市西湖区灵隐街道西溪路 128 | 号 | | | 首席合伙人 | 钟建国 | 上年末合伙人数量 人 | | 241 | | 上年末执业人 员数量 | 注册会计师 | 人 | | 2,356 | | | | 签署过证券服务业务审计报告的注册会计师 人 | | 904 | | 2023 年（经审 | 业务收入总额 | 34.83 | 亿元 | | | 计）业务收入 | ...